Eli Lilly and Co.

Part of Mississippi's Zyprexa case against Lilly dismissed

December 2, 2009
 IBJ Staff
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges improper marketing of antipsychotic drug Zyprexa for unapproved uses.
More

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Lilly's Cymbalta wins new approval for anxiety disorder

November 30, 2009
J.K. Wall
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
More

Lilly stock droops after rival claims faster-acting impotence pill

November 18, 2009
 IBJ Staff
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
More

Lilly to pay Utah $24 million to settle Zyprexa suit

November 11, 2009
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic drug Zyprexa.
More

Lilly, WellPoint CEOs pin hopes on Senate

November 11, 2009
J.K. Wall
Drugmaker and health insurer bemoan aspects of House health reform bill and hope Senate crafts more industry-friendly bill.
More

Lilly reducing sales force by 191 as part of larger restructuring

November 2, 2009
Eli Lilly and Co. has notified the state that it plans to eliminate 191 sales jobs as part of a company-wide restructuring announced in September that ultimately will result in 5,500 job cuts by the end of 2011.
More

TechPoint to focus on IT firms specializing in medical, life sciences sectorsRestricted Content

October 31, 2009
Chris O'Malley
Long tracking the emergence of information technology firms involved in the health and life sciences sector, the state’s IT trade group, TechPoint, is undergoing a mitosis of sorts to help fuel the trend. It has created Advancing Life Science & Health Care Information Technology, or ALHIT, which will focus on growing this subset of the IT realm.
More

Lilly opens new biotech center in San Diego

October 29, 2009
J.K. Wall
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
More

Lilly to move 1,000 from Faris campus

October 26, 2009
J.K. Wall
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate center by mid-2010.
More

Lilly needs to sell more Effient before Zyprexa loses patent protectionRestricted Content

October 24, 2009
J.K. Wall
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for the quarter.
More

Lilly settles Zyprexa case with S. Carolina for $45M

October 23, 2009
 IBJ Staff and Associated Press
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker Eli Lilly and Co. over the company's marketing of an anti-psychotic drug.
More

Eli Lilly CEO banking on new drug pipeline

October 22, 2009
Associated Press
CEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year career at the company. He's betting there will be a fourth.
More

Lilly, GE announce cancer diagnostic breakthrough

October 21, 2009
J.K. Wall
Eli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
More

Uncertainty over drug pipeline sends Lilly shares down

October 21, 2009
J.K. Wall
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products aren't likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
More

Lilly reports $942 million profit in third quarter

October 21, 2009
J.K. Wall
Excluding special items, Eli Lilly and Co.'s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog sales. Lilly's revenue rose 7 percent in the quarter over the same period of 2008, to $5.56 billion.
More

Medco plans to compare Plavix, Effient in study

October 20, 2009
 IBJ Staff and Associated Press
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
More

German company to buy Eli Lilly's Lafayette plantRestricted Content

October 17, 2009
J.K. Wall
Eli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing its work force by 5,500 employees and cutting its operating expenses by $1 billion.
More

Lilly to pay Idaho $13M in drug settlement

October 14, 2009
 IBJ Staff and Associated Press
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of anti-psychotic drug Zyprexa.
More

Lilly to sell Lafayette plant to German firm

October 14, 2009
J.K. Wall
Nearly 700 workers will be offered severance, new jobs
More

Baucus health reform bill would stick Indiana companies with fees

October 10, 2009
 IBJ Staff
The health reform bill sponsored by U.S. Sen. Max Baucus, D-Mont., would help pay for expanded health insurance coverage by levying fees of $13 billion a year on the health care industry. The fees would deliver a hefty bill to just about all of Indiana’s major health care companies. But how they’re reacting to the fees is all over the map.
More

Lilly settles Zyprexa suit with S. Carolina

October 7, 2009
 IBJ Staff
Eli Lilly and Co. has agreed to settle the State of South Carolina's lawsuit that claimed Lilly improperly marketed the antipsychotic drug Zyprexa, according to Bloomberg News.
More

Lilly's win in Evista patent case crucial, analyst says

September 24, 2009
Scott Olson
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major victory for the company, says an analyst who closely follows the pharmaceutical industry.
More

Judge upholds Lilly's Evista patent

September 24, 2009
J.K. Wall
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced late yesterday.
More

Lilly agrees to settle more state Zyprexa suits

September 22, 2009
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
More
Page  << 21 22 23 24 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The east side does have potential...and I have always thought Washington Scare should become an outlet mall. Anyone remember how popular Eastgate was? Well, Indy has no outlet malls, we have to go to Edinburgh for the deep discounts and I don't understand why. Jim is right. We need a few good eastsiders interested in actually making some noise and trying to change the commerce, culture and stereotypes of the East side. Irvington is very progressive and making great strides, why can't the far east side ride on their coat tails to make some changes?

  2. Boston.com has an article from 2010 where they talk about how Interactions moved to Massachusetts in the year prior. http://www.boston.com/business/technology/innoeco/2010/07/interactions_banks_63_million.html The article includes a link back to that Inside Indiana Business press release I linked to earlier, snarkily noting, "Guess this 2006 plan to create 200-plus new jobs in Indiana didn't exactly work out."

  3. I live on the east side and I have read all your comments. a local paper just did an article on Washington square mall with just as many comments and concerns. I am not sure if they are still around, but there was an east side coalition with good intentions to do good things on the east side. And there is a facebook post that called my eastside indy with many old members of the eastside who voice concerns about the east side of the city. We need to come together and not just complain and moan, but come up with actual concrete solutions, because what Dal said is very very true- the eastside could be a goldmine in the right hands. But if anyone is going damn, and change things, it is us eastside residents

  4. Please go back re-read your economics text book and the fine print on the February 2014 CBO report. A minimum wage increase has never resulted in a net job loss...

  5. The GOP at the Statehouse is more interested in PR to keep their majority, than using it to get anything good actually done. The State continues its downward spiral.

ADVERTISEMENT